Abstract
Objective
This study was performed to clarify factors that might influence short-term side effects occurring within 96 hours after administration of131I for patients with thyroid carcinoma.Methods: In 71 patients with differentiated thyroid carcinoma, short-term side effects including gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache were retrospectively analyzed. All patients were given domperidone for prevention of gastrointestinal complaints and advised to consume sour foods to promote discharge of radioiodine from the salivary glands. Selected factors possibly affecting the incidence of side effects were dose per body weight, TSH, effective half-life of131I, sex, age,131I accumulation into the stomach and salivary glands, and edema prior to radioiodine administration. The factors were evaluated by multivariate analyses.
Results
Incidence of gastrointestinal complaints, salivary gland swelling with pain, change in taste and headache was 65.2%, 50.0%, 9.8% and 4.4%, respectively. In gastrointestinal complaints, the incidence of appetite loss, nausea and vomiting was 60.9%, 40.2% and 7.6%, respectively. The gastrointestinal complaints increased significantly in the patients dosed above 55.5 MBq/kg and with TSH elevation. For salivary gland swelling with pain, female patients displayed a significantly higher incidence than males. No statistically significant factors were detected for change in taste or headache.
Conclusions
Significant factors influencing short-term side effects were dose per body weight and TSH values for gastrointestinal complaints, and female sex for salivary gland swelling with pain. Our preliminary experience suggests that the most frequent gastrointestinal complaints can be prevented with ramosetron.
Similar content being viewed by others
References
Van Nostrand D, Neutze J, Atkins F. Side effects of “rational dose” iodine-131 therapy for metastatic well-differentiated thyroid carcinoma.J Nucl Med 1986; 27:1519–1527.
Lin W, Shen YY, Wang SJ. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients.Clin Nucl Med 1996; 21:780–782.
Mazzaferri EL. Radioiodine and other treatments and outcome. In:Werner and Ingbar’s the Thyroid, Braverman L, Utiger RD (eds), Philadelphia; Lippincott-Raven Publishers, 1996: 922–945.
Zettinig G, Hanselmayer G, Fueger BJ, Hofmann A, Pirich C, Nepp J, et al. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study.Eur J Nucl Med 2002; 29:1428–1432.
Bohuslavizki KH, Brenner W, Klutmann S, Hubner RH, Lassmann S, Feyerabend B, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.J Nucl Med 1998; 39:1237–1242.
Solans R, Bosch JA, Galofre P, Porta F, Rosello J, Selva-O’Callagan A, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.J Nucl Med 2001; 42:738–743.
Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma.J Nucl Med 1998; 39:1551–1554.
Levy HA, Park CH. Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer.Clin Nucl Med 1987; 12:303–307.
Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).J Clin Endcrinol Metab 1994; 78:188–196.
Krausz Y, Uziely B, Nesher R, Chisin R, Glaser B. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.Isr Med Assoc 2001; 11:843–849.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kita, T., Yokoyama, K., Higuchi, T. et al. Multifactorial analysis on the short-term side effects occurring within 96 hour after radioiodine-131 therapy for differentiated thyroid carcinoma. Ann Nucl Med 18, 345–349 (2004). https://doi.org/10.1007/BF02984474
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02984474